"Yohimbine + Hydrocortisone"

Phase 2Small molecule

"Yohimbine + Hydrocortisone" is one of 37 small molecule programs targeting Opioid Use Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Opioid Use DisorderActive, not recruiting

Opioid Use DisorderPhase 2

Active, not recruiting

Competition

Competitive Landscape

116 competitors in Opioid Use Disorder

#DrugCompanyPhaseTrials

Revia

Teva

Phase 3

2 2

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

4 3

Epidiolex

Jazz Pharmaceuticals

Phase 2

5 4

Dayvigo

Eisai

Phase 2

2 5

Ozempic

Novo Nordisk

Phase 2

1 6

Vraylar

AbbVie

Phase 2

1 7

Mounjaro

Eli Lilly

Phase 2

1 8

Victoza

Novo Nordisk

Phase 2

1 9

Diamox

Teva

Phase 2

—10

Buprenorphine/naloxone

Astellas

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Opioid Use Disorder

NCT04231708

Clinical

Trials by Indication[1]

Attention1 trial

The Role of Stress Neuromodulators in Decision Making Under Risk and Selective Attention to Threat

Completed·—·N/A·NCT04359147·167 enrolled

Opioid Use1 trial

Using rTMS to Explore Neural Mechanisms of Stress-Induced Opioid Use

Withdrawn·WWayne State University·Phase 2·NCT04181515

Opioid Use Disorder1 trial

Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder

Not yet recruiting·WWayne State University·Phase 2·NCT04231708·20 enrolled

Stress1 trial

rTMS of Limbic Circuitry in Stress Modulation in Healthy Volunteers

Withdrawn·WWayne State University·Phase 2·NCT04180969

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for "Yohimbine + Hydrocortisone". U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — "Yohimbine + Hydrocortisone" compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for "Yohimbine + Hydrocortisone". EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wayne State University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWayne State University

"Yohimbine + Hydrocortisone"

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Attention1 trial

Opioid Use1 trial

Opioid Use Disorder1 trial

Stress1 trial

References

Drug Info

Quick Facts

Related News